PGM2

Across TCGA pan-cancer cohorts, PGM2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PGM2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PGM2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PGM2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where PGM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.486	0.259	.001	61	view →
CCRCC	DFS	Tertile	III,IV	0.763	0.341	.003	37	view →
UCEC	DFS	Median	All	0.959	0.850	.024	4	view →
LUAD	DFS	Tertile	II,III,IV	0.726	1.000	.018	4	view →
LSCC	DFS	Median	II,III,IV	0.444	0.883	.030	2	view →
HNSC	DFS	Median	IV	0.924	1.000	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PGM2–PDAC (DFS)

Open the PDAC breakdown →